As weight-loss injections like Mounjaro and Wegovy soar in popularity across the UK, jewellers say they’re seeing an unexpected side effect: wedding and engagement rings no longer fit, and in they are ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.